Precede Biosciences closed an $83.5 million Series B and secured a $20 million strategic credit facility to scale its liquid biopsy platform for pharma partnerships, bringing total new capital to $103.5 million in financing and credit. The Boston‑based company provides genome‑wide expression profiling of cancer surface proteins from blood and combines NGS with machine learning to inform drug development. Precede said it is already working with about half of the top 20 pharma companies and has partnerships supporting roughly 30 investigational medicines. The financing will expand capacity to support trials and companion diagnostic work, with stated interest in ADCs, radiopharmaceuticals and emerging modalities. CEO Rehan Verjee framed the raise as necessary to meet growing demand from drug developers seeking blood‑based assays to identify responders, characterize mechanisms of resistance and refine patient selection strategies.